Skip to content

Study · Non-randomized trial · n = 6 · 1997

3 results

Growth hormone increases and insulin-like growth factor-I decreases circulating lipoprotein(a)

Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DE

European journal of endocrinology1 Apr 1997Cited by 25 (Europe PMC)

PMID9150696 (opens in a new tab)DOI10.1530/eje.0.1360377 (opens in a new tab)PepBankPUB-09150696
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In prepubertal boys with idiopathic short stature, serum IGF-I rose significantly during intranasal hexarelin treatment.

    In plain wordsIn short boys before puberty, intranasal hexarelin was followed by a rise in IGF-I.

    Peptide
    Hexarelin
    Outcome
    IncreaseSerum IGF-I change
    Study

    n = 6

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    60 micrograms t.i.d. · intranasal · 6-9 monthsAs given in this study (human).

    Source sentences

    Summary
    Serum IGF-I rose significantly in all the subjects in all four groups.
    1 context sentence
    Summary · context
    group c: prepubertal boys with idiopathic short stature (n = 6) treated with the GH secretagogue (GHRP) hexarelin (60 micrograms t.i.d. intranasally)
  2. 02HumanNon-randomized trialEfficacy outcome

    In prepubertal boys with idiopathic short stature, intranasal hexarelin increased serum Lp(a) by 102% (P < 0.01).

    In plain wordsIn short boys before puberty, intranasal hexarelin was followed by a rise in blood lipoprotein(a), a heart disease risk marker.

    Peptide
    Hexarelin
    Outcome
    IncreaseSerum Lp(a) change
    Study

    n = 6

    Outcome group
    Lipids · Cardiovascular
    Studied dose
    60 micrograms t.i.d. · intranasal · 6-9 monthsAs given in this study (human).

    Measurements

    Lp(a) change
    102%
    hexarelin group

    Source sentences

    Summary
    In the first three groups in which IGF-I was elevated by exogenous or endogenous GH stimulation, serum Lp(a) increased significantly (119 +/- 35%, P < 0.01; 126 +/- 44%, P < 0.05; 102 +/- 29%, P < 0.01 for groups a, b, and c respectively).
    1 context sentence
    Summary · context
    group c: prepubertal boys with idiopathic short stature (n = 6) treated with the GH secretagogue (GHRP) hexarelin (60 micrograms t.i.d. intranasally)
  3. 03HumanNon-randomized trialEfficacy outcome

    In prepubertal boys with idiopathic short stature, intranasal hexarelin increased insulin by 353.8% (P < 0.01).

    In plain wordsIn short boys before puberty, intranasal hexarelin was followed by a rise in blood insulin.

    Peptide
    Hexarelin
    Outcome
    IncreaseSerum insulin change
    Study

    n = 6

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    60 micrograms t.i.d. · intranasal · 6-9 monthsAs given in this study (human).

    Measurements

    Insulin change
    353.8%
    hexarelin group

    Source sentences

    Summary
    Insulin was significantly increased in all the subjects receiving hGH or GHRP (65.2 +/- 31%, P = 0.109; 93.7 +/- 53%, P = 0.062; 353.8 +/- 52.7%, P < 0.01 for groups a, b, and c respectively) whereas insulin levels were reduced following exogenous administration of IGF-I (-34.1 +/- 9.1%, P < 0.01).
    1 context sentence
    Summary · context
    group c: prepubertal boys with idiopathic short stature (n = 6) treated with the GH secretagogue (GHRP) hexarelin (60 micrograms t.i.d. intranasally)

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.